Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation
Key facts
- Who runs it
- Ting YANG
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 6 May 2021
- Ended
- 18 Jun 2025
- Type of study
- Observational
- Treatments tested
- SE-SPTM-PCR microRNA assay
- Record updated
- 18 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Patients who received allogeneic hematopoietic stem cell transplantation (HSCT)
- Availability of archived plasma samples collected within 100 days post-transplant
- Documented CMV DNA testing results corresponding to the plasma sample
- Age ≥ 18 years
Who cannot take part
- Concurrent active infections with other viruses (e.g., EBV, HBV, HCV) at time of plasma collection
- Patients who received investigational antiviral therapy within 2 weeks prior to sample collection
- Lack of corresponding CMV DNA testing results
- Inadequate volume or quality of archived plasma sample for analysis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT). Specifically, the study retrospectively analyzes plasma samples to determine whether hcmv-miR-UL22A-5p can serve as a sensitive and specific biomarker for CMV reactivation. Results will be compared to traditional CMV DNA testing methods.
The group in the trial
- HSCT Patient Group
This group includes patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). Archived plasma samples from these patients are used to evaluate the performance of the SE-SPTM-PCR platform for detecting hcmv-miR-UL22A-5p. Each sample has a corresponding CMV DNA test result, which serves as the reference standard for assessing the diagnostic accuracy of the microRNA-based detection method.
Treatment: SE-SPTM-PCR microRNA assay
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Retrospective Clinical Validation of the SE-SPTM-PCR Platform for Hcmv-miR-UL22A-5p Detection in Monitoring Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation
- Record updated
- 18 September 2025